
Prema Maria Mertz
Examiner (ID: 426, Phone: (571)272-0876 , Office: P/1646 )
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1674, 1646, 1621, 1812 |
| Total Applications | 2681 |
| Issued Applications | 1589 |
| Pending Applications | 444 |
| Abandoned Applications | 675 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17895442
[patent_doc_number] => 20220305104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => METHODS OF TREATING ATOPIC DERMATITIS
[patent_app_type] => utility
[patent_app_number] => 17/696028
[patent_app_country] => US
[patent_app_date] => 2022-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40011
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17696028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/696028 | Methods of treating atopic dermatitis | Mar 15, 2022 | Issued |
Array
(
[id] => 17734720
[patent_doc_number] => 20220220179
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => FUSION PROTEIN COMPRISING IL13
[patent_app_type] => utility
[patent_app_number] => 17/693956
[patent_app_country] => US
[patent_app_date] => 2022-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -223
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17693956
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/693956 | Fusion protein comprising IL13 | Mar 13, 2022 | Issued |
Array
(
[id] => 17867099
[patent_doc_number] => 20220289834
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody
[patent_app_type] => utility
[patent_app_number] => 17/691219
[patent_app_country] => US
[patent_app_date] => 2022-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691219
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/691219 | Method of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL23 specific antibody | Mar 9, 2022 | Issued |
Array
(
[id] => 20336505
[patent_doc_number] => 20250340625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/556651
[patent_app_country] => US
[patent_app_date] => 2022-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556651
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/556651 | ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF | Mar 9, 2022 | Pending |
Array
(
[id] => 19809518
[patent_doc_number] => 12240889
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-04
[patent_title] => Decoy cytokine receptor
[patent_app_type] => utility
[patent_app_number] => 17/687554
[patent_app_country] => US
[patent_app_date] => 2022-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 75
[patent_no_of_words] => 29462
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17687554
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/687554 | Decoy cytokine receptor | Mar 3, 2022 | Issued |
Array
(
[id] => 19491647
[patent_doc_number] => 12110343
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-08
[patent_title] => Anti-plasma kallikrein antibodies
[patent_app_type] => utility
[patent_app_number] => 17/684460
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 5
[patent_no_of_words] => 13930
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684460
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684460 | Anti-plasma kallikrein antibodies | Mar 1, 2022 | Issued |
Array
(
[id] => 17672711
[patent_doc_number] => 20220185878
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => BIOPHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/684907
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684907
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684907 | Biopharmaceutical compositions | Mar 1, 2022 | Issued |
Array
(
[id] => 17830125
[patent_doc_number] => 20220267429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/684305
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684305
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684305 | Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders | Feb 28, 2022 | Issued |
Array
(
[id] => 19425078
[patent_doc_number] => 12084481
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => HV1 modulators and uses
[patent_app_type] => utility
[patent_app_number] => 17/684346
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 35
[patent_no_of_words] => 21839
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684346
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684346 | HV1 modulators and uses | Feb 28, 2022 | Issued |
Array
(
[id] => 19217893
[patent_doc_number] => 20240182597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES
[patent_app_type] => utility
[patent_app_number] => 18/547663
[patent_app_country] => US
[patent_app_date] => 2022-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18072
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -48
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547663
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/547663 | ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES | Feb 27, 2022 | Pending |
Array
(
[id] => 20756214
[patent_doc_number] => 12648963
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-09
[patent_title] => MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function
[patent_app_type] => utility
[patent_app_number] => 18/546936
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 66
[patent_figures_cnt] => 84
[patent_no_of_words] => 22351
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546936
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/546936 | MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function | Feb 17, 2022 | Issued |
Array
(
[id] => 17655454
[patent_doc_number] => 20220175919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => THERAPEUTIC AGENTS FOR PANCREATIC CANCER
[patent_app_type] => utility
[patent_app_number] => 17/674989
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/674989 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER | Feb 17, 2022 | Abandoned |
Array
(
[id] => 20756214
[patent_doc_number] => 12648963
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-09
[patent_title] => MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function
[patent_app_type] => utility
[patent_app_number] => 18/546936
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 66
[patent_figures_cnt] => 84
[patent_no_of_words] => 22351
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546936
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/546936 | MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function | Feb 17, 2022 | Issued |
Array
(
[id] => 19112837
[patent_doc_number] => 20240124587
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => MULTI-DOMAIN FUSION PROTEIN AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/277996
[patent_app_country] => US
[patent_app_date] => 2022-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10997
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277996
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/277996 | MULTI-DOMAIN FUSION PROTEIN AND USE THEREOF | Feb 16, 2022 | Pending |
Array
(
[id] => 19020190
[patent_doc_number] => 20240076361
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => ANTI-PT217 TAU ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 18/273355
[patent_app_country] => US
[patent_app_date] => 2022-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19979
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273355
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/273355 | ANTI-PT217 TAU ANTIBODY | Feb 16, 2022 | Pending |
Array
(
[id] => 19563545
[patent_doc_number] => 12138296
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-12
[patent_title] => Formulations for bovine granulocyte colony stimulating factor and variants thereof
[patent_app_type] => utility
[patent_app_number] => 17/591553
[patent_app_country] => US
[patent_app_date] => 2022-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14272
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17591553
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/591553 | Formulations for bovine granulocyte colony stimulating factor and variants thereof | Feb 1, 2022 | Issued |
Array
(
[id] => 17611532
[patent_doc_number] => 20220153811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => Advanced Avatar Dendritic Cells
[patent_app_type] => utility
[patent_app_number] => 17/588949
[patent_app_country] => US
[patent_app_date] => 2022-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10003
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/588949 | Advanced avatar dendritic cells | Jan 30, 2022 | Issued |
Array
(
[id] => 17734736
[patent_doc_number] => 20220220195
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => ANTIBODY TO HUMAN IL-1 BETA
[patent_app_type] => utility
[patent_app_number] => 17/587751
[patent_app_country] => US
[patent_app_date] => 2022-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587751
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/587751 | ANTIBODY TO HUMAN IL-1 BETA | Jan 27, 2022 | Abandoned |
Array
(
[id] => 19396145
[patent_doc_number] => 12070474
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-27
[patent_title] => Methods and compositions for natural killer cells
[patent_app_type] => utility
[patent_app_number] => 17/585126
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 13
[patent_no_of_words] => 14469
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585126
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/585126 | Methods and compositions for natural killer cells | Jan 25, 2022 | Issued |
Array
(
[id] => 17734724
[patent_doc_number] => 20220220183
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/583971
[patent_app_country] => US
[patent_app_date] => 2022-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15554
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583971
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/583971 | Compositions and methods relating to the treatment of diseases | Jan 24, 2022 | Issued |